-
Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer’s Disease Initiating Cholinesterase Inhibitors Drugs Aging (IF 2.8) Pub Date : 2024-03-11 Ashna Talwar, Satabdi Chatterjee, Jeffrey Sherer, Susan Abughosh, Michael Johnson, Rajender R. Aparasu
-
-
Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma Drugs Aging (IF 2.8) Pub Date : 2024-03-06 Luke S. McLean, Annette M. Lim, Mathias Bressel, Alesha A. Thai, Danny Rischin
-
Management of Scleritis in Older Adults Drugs Aging (IF 2.8) Pub Date : 2024-03-05
Abstract Scleritis, an inflammatory disease of the eye affecting scleral tissue, presents unique challenges in the older adult population. Unlike their younger counterparts, older individuals manifest a distinct spectrum of the disease with different underlying etiologies, co-morbidities, altered immune function, and an increased risk of systemic side effects from medication choices. Addressing these
-
Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults Drugs Aging (IF 2.8) Pub Date : 2024-02-28 Emily Schehlein, Alan Robin
Glaucoma is a leading cause of irreversible blindness which preferentially affects older individuals. No medications or therapies which are currently in our arsenal actually treat glaucoma itself. We know that intraocular pressure (IOP) is currently the only modifiable risk factor for glaucoma. The primary treatments for glaucoma include medications, laser therapies, and surgical therapies. The Rho
-
The Effects of Pharmacological Urate-Lowering Therapy on Cardiovascular Disease in Older Adults with Gout Drugs Aging (IF 2.8) Pub Date : 2024-02-28 Martijn Gerritsen, Mike T. Nurmohamed
Cardiovascular disease is an important cause of mortality in older patients. In addition to the traditional risk factors for cardiovascular disease, hyperuricemia has been increasingly associated with an elevated risk of cardiovascular disease. Uric acid itself has several unfavorable effects on the cardiovascular system, and hyperuricemia can lead to the development of gout. Gout is the most prevalent
-
The Difficulties of Managing Pain in People Living with Frailty: The Potential for Digital Phenotyping Drugs Aging (IF 2.8) Pub Date : 2024-02-24 Jemima T. Collins, David A. Walsh, John R. F. Gladman, Monica Patrascu, Bettina S. Husebo, Esmee Adam, Alison Cowley, Adam L Gordon, Giulia Ogliari, Hanneke Smaling, Wilco Achterberg
-
Post-Stroke Depression in Older Adults: An Overview Drugs Aging (IF 2.8) Pub Date : 2024-02-23 Fabio Giuseppe Masuccio, Erica Grange, Rachele Di Giovanni, Martina Rolla, Claudio Marcello Solaro
-
Impact of Immunosenescence in Older Kidney Transplant Recipients: Associated Clinical Outcomes and Possible Risk Stratification for Immunosuppression Reduction Drugs Aging (IF 2.8) Pub Date : 2024-02-22
Abstract The number of older individuals receiving a kidney transplant as replacement therapy has significantly increased in the past decades and this increase is expected to continue. Older patients have a lower rate of acute rejection but an increased incidence of death with a functioning graft. Several factors, including an increased incidence of infections, post-transplant malignancy and cardiovascular
-
Proton Pump Inhibitor Use and the Risk of Cardiovascular Complications and Death in Older Adults with Diabetes: A Population-Based Cohort Study Drugs Aging (IF 2.8) Pub Date : 2024-02-17 Andreana Foresta, Luisa Ojeda Fernandez, Ginevra Torrigiani, Simone Schena, Maria Carla Roncaglioni, Alessandro Nobili, Mauro Tettamanti, Carlotta Franchi, Ida Fortino, Elena Succurro, Giorgio Sesti, Marta Baviera
-
Helicobacter pylori Eradication Treatment in Older Patients Drugs Aging (IF 2.8) Pub Date : 2024-02-10 Paulius Jonaitis, Juozas Kupcinskas, Javier P. Gisbert, Laimas Jonaitis
-
Development and Pilot Testing of an Algorithm-Based Approach to Anticholinergic Deprescribing in Older Patients Drugs Aging (IF 2.8) Pub Date : 2024-02-06
Abstract Background Adverse anticholinergic drug reactions are common, yet evidence on how to reduce exposure to anticholinergic activity and reliably measure successful deprescribing is still scant. This study proposes an algorithm-based approach to evaluate and reduce anticholinergic load, and reports the results of its pilot testing. Methods Based on published evidence and expert opinion, a list
-
The Current Landscape of Pharmacotherapies for Sarcopenia Drugs Aging (IF 2.8) Pub Date : 2024-02-05 Gulistan Bahat, Serdar Ozkok
-
Unlocking Deprescribing Potential in Nursing Homes: Insights from a Focus Group Study with Healthcare Professionals Drugs Aging (IF 2.8) Pub Date : 2024-01-29 Anne G. R. Visser, Jenny B. G. Poddighe de-Bruijn, Bart Spaetgens, Bjorn Winkens, Rob Janknegt, Jos M. G. A. Schols
Background The nursing home population is characterized by multimorbidity and disabilities, which often result in extensive prescription of medication and subsequent polypharmacy. Deprescribing, a planned and supervised process of dose reduction or total cessation of medication, is a solution to combat this. Objective This study aimed to identify barriers and enablers of deprescribing as experienced
-
Are Lists of Potentially Inappropriate Medications Associated with Hospital Readmissions? A Systematic Review Drugs Aging (IF 2.8) Pub Date : 2024-01-25 Camille Schwab, Alice Clementz, Agnès Dechartres, Christine Fernandez, Patrick Hindlet
-
Evaluating Provider and Pharmacy Discordance in Potential Calcium Channel Blocker–Loop Diuretic Prescribing Cascade Drugs Aging (IF 2.8) Pub Date : 2024-01-22 Asinamai M. Ndai, Earl J. Morris, Almut G. Winterstein, Scott M. Vouri
-
Diagnosis and Pharmacological Management of Microscopic Colitis in Geriatric Care Drugs Aging (IF 2.8) Pub Date : 2024-01-17 Ole Haagen Nielsen, Darrell S. Pardi
-
Do Proton Pump Inhibitors Reduce Upper Gastrointestinal Bleeding in Older Patients with Atrial Fibrillation Treated with Oral Anticoagulants? A Nationwide Cohort Study in France Drugs Aging (IF 2.8) Pub Date : 2023-12-20
Abstract Background Proton pump inhibitors (PPIs) are largely used in older adults and data are needed in off-label indications, such as the prevention of upper gastrointestinal bleeding (UGIB) in patients receiving oral anticoagulants (OACs). This study aimed to assess whether PPIs reduce the risk of UGIB in patients initiating oral anticoagulation. Methods We conducted a longitudinal study based
-
Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study Including 871 Patients Drugs Aging (IF 2.8) Pub Date : 2023-12-20 Roos F. Bleckman, K. Esther Broekman, Evelyne Roets, Mohammed Mohammadi, Ingrid M. E. Desar, Hans Gelderblom, Ron H. J. Mathijssen, Neeltje Steeghs, Pauline de Graeff, Anna K. L. Reyners
-
Potentially Inappropriate Psychotropic Drugs in Nursing Homes: An Italian Observational Study Drugs Aging (IF 2.8) Pub Date : 2023-11-30 Marina Azab, Alessio Novella, Aladar Ianes, Luca Pasina
-
A Trial-Based Cost-Utility Analysis of a Medication Optimization Intervention Versus Standard Care in Older Adults Drugs Aging (IF 2.8) Pub Date : 2023-11-22 Eirin Guldsten Robinson, Hanna Gyllensten, Jeanette Schultz Johansen, Kjerstin Havnes, Anne Gerd Granas, Trine Strand Bergmo, Lars Småbrekke, Beate Hennie Garcia, Kjell H. Halvorsen
-
Cutaneous Lupus Erythematosus: Review and Considerations for Older Populations Drugs Aging (IF 2.8) Pub Date : 2023-11-22 Briana Heinly, Astia Allenzara, Matthew Helm, Galen T. Foulke
-
Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize Trial Drugs Aging (IF 2.8) Pub Date : 2023-11-20 Cynthia M. Boyd, Susan M. Shetterly, John D. Powers, Linda A. Weffald, Ariel R. Green, Orla C. Sheehan, Emily Reeve, Melanie L. Drace, Jonathan D. Norton, Mahesh Maiyani, Kathy S. Gleason, Jennifer K. Sawyer, Matthew L. Maciejewski, Jennifer L. Wolff, Courtney Kraus, Elizabeth A. Bayliss
-
Potentially inappropriate prescribing in multimorbid and polymedicated older adults with AF: A Systematic Review and Meta-Analysis Drugs Aging (IF 2.8) Pub Date : 2023-11-17 Cheima Amrouch, Delphine Vauterin, Souad Amrouch, Maxim Grymonprez, Lu Dai, Cecilia Damiano, Amaia Calderón-Larrañaga, Lies Lahousse, Dirk De Bacquer, Gregory Y. H. Lip, Davide L. Vetrano, Delphine De Smedt, Mirko Petrovic
-
Prevalence and factors associated with inappropriate dosing of apixaban and rivaroxaban in hospitalized older adults with atrial fibrillation: a cross-sectional study Drugs Aging (IF 2.8) Pub Date : 2023-11-13 Théodore Decaix, Kenza Kemmache, Pierre Gay, Olivier Laprévote, Flora Ketz, Éric Pautas
-
Factors Associated with Psychotropic Medication Use in People Living with Dementia in the Community: A Systematic Review and Meta-Analysis Drugs Aging (IF 2.8) Pub Date : 2023-11-09 Kerryn L. Loftus, Anne P. F. Wand, Juanita L. Breen, Glenn E. Hunt, Carmelle Peisah
-
Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: The GeroCovid Vax Study Drugs Aging (IF 2.8) Pub Date : 2023-11-08 Caterina Trevisan, Labjona Haxhiaj, Alba Malara, Angela Abbatecola, Giorgio Fedele, Annapina Palmieri, Pasqualina Leone, Ilaria Schiavoni, Paola Stefanelli, Stefania Maggi, Giuseppe Sergi, Stefano Volpato, Raffaele Antonelli Incalzi, Graziano Onder
-
Current Pharmacological Therapies for the Management of Spondyloarthritis: Special Considerations in Older Patients Drugs Aging (IF 2.8) Pub Date : 2023-10-30 Renaud Felten, Eric Toussirot
Spondylarthritis (SpA) is generally observed in young male patients but can be diagnosed in older patients. These cases correspond to late-onset SpA (LoSpA) with two main clinical presentations, axial and peripheral SpA. Another increasingly common situation is that of older patients who have had SpA for many years. The therapeutic management of LoSpA is quite smilar to the management of patients with
-
NSAIDs for Pain Control During the Peri-Operative Period of Hip Fracture Surgery: A Systematic Review Drugs Aging (IF 2.8) Pub Date : 2023-10-25 Wilhelm Pommier, Elise-Marie Minoc, Pierre-Marie Morice, Pascale Lescure, Cyril Guillaume, Claire Lafont, Marc-Olivier Fischer, Jacques Boddaert, Sara Thietart, Véronique Lelong-Boulouard, Bérengère Beauplet, Cédric Villain
-
Anti-VEGF Drugs in Age-Related Macular Degeneration: A Focus on Dosing Regimen-Related Safety and Efficacy Drugs Aging (IF 2.8) Pub Date : 2023-10-20 Haibei Ma, Hai Wei, Chunpu Zou, Guoqin Zhu, Qi Gao, Ning Zhang, Bing Wang
-
Prescribing Cascades with Recommendations to Prevent or Reverse Them: A Systematic Review Drugs Aging (IF 2.8) Pub Date : 2023-10-20 Oriane Adrien, Atiya K. Mohammad, Jacqueline G. Hugtenburg, Lisa M. McCarthy, Simone Priester-Vink, Robbert Visscher, Patricia M. L. A. van den Bemt, Petra Denig, Fatma Karapinar-Carkıt
-
Prevalence of and Risk Factors for Drug-Related Readmissions in Older Adults: A Systematic Review and Meta-Analysis Drugs Aging (IF 2.8) Pub Date : 2023-10-21 Narisha Prasad, Edward C. Y. Lau, Ilsa Wojt, Jonathan Penm, Zhaoli Dai, Edwin C. K. Tan
-
Five-Year Follow-Up of Diabetic Complications and Geriatric Alterations in French Older Patients with Type 2 Diabetes According to Treatment Modalities: The Observational Prospective GERODIAB Cohort Drugs Aging (IF 2.8) Pub Date : 2023-10-18 Jean Doucet, Olivia Guérin, Caroline Hilbert, Lyse Bordier, Julien Wils, Jacques Bénichou, Bernard Bauduceau
-
Low-Income Older Adults’ Vulnerability to Anticholinergic Medication-Associated Frailty Drugs Aging (IF 2.8) Pub Date : 2023-10-19 Lana Sargent, Kristin M. Zimmerman, Almutairi Mohammed, Matthew J. Barrett, Huma Nawaz, Kathryn Wyman-Chick, Marissa Mackiewicz, Youssef Roman, Patricia Slattum, Sally Russell, Dave L. Dixon, Sarah K. Lageman, Sarah Hobgood, Leroy R. Thacker, Elvin T. Price
-
Patient Perceptions of Opioids and Benzodiazepines and Attitudes Toward Deprescribing Drugs Aging (IF 2.8) Pub Date : 2023-10-04 Casey J. Kelley, Joshua D. Niznik, Stefanie P. Ferreri, Courtney Schlusser, Lori T. Armistead, Tamera D. Hughes, Cristine B. Henage, Jan Busby-Whitehead, Ellen Roberts
Background Opioids and benzodiazepines (BZDs) pose a public health problem. Older adults are especially susceptible to adverse events from opioids and BZDs owing to an increased usage of opioids and BZDs, multiple comorbidities, and polypharmacy. Deprescribing is a possible, yet challenging, solution to reducing opioid and BZD use. Objective We aimed to explore older adult patients’ knowledge of opioids
-
The PROMISING Project: A Pilot Study to Improve Geriatric Care Through a Pharmacist-Led Psychotropic Stewardship Program Drugs Aging (IF 2.8) Pub Date : 2023-09-27 Marie d’Amours, Farah Ettis, Lauriane Ginefri, Johnny Lim, Angela-Sinlan Lin Poo Yuan, Jennifer Fontaine, Dana Wazzan, David Williamson, Vincent Dagenais-Beaulé
Background and objective Psychotropic medications are frequently prescribed during acute care, even in older patients. They represent a risk for inappropriate long-term use and increase the overall risk of morbidity and mortality in this population. Our project aimed to evaluate the feasibility of a psychotropic medication stewardship program led by pharmacists. Methods We conducted a prospective,
-
Crushed Tablet Administration for Patients with Dysphagia and Enteral Feeding: Challenges and Considerations Drugs Aging (IF 2.8) Pub Date : 2023-09-14 Amie Blaszczyk, Nicole Brandt, Jeremy Ashley, Nancy Tuders, Hannah Doles, Richard G. Stefanacci
Dysphagia is increasingly common in older adults; it is especially prevalent in long-term care settings. Patients with dysphagia likely require pharmacologic treatment for multiple comorbidities but may find it difficult or impossible to swallow oral medications. Administering crushed medications mixed with a soft food or liquid vehicle, or via a feeding tube, is a common strategy to circumvent swallowing
-
Secular Trends in Central Nervous System-Active Polypharmacy Among Serial Cross-Sections of US Adults, 2009–2020 Drugs Aging (IF 2.8) Pub Date : 2023-09-11 Samuel W. Terman, Joshua D. Niznik, Matthew E. Growdon, Lauren B. Gerlach, James F. Burke
-
Systematic Review and Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults: An Update Drugs Aging (IF 2.8) Pub Date : 2023-09-13 Shelly L. Gray, Subashan Perera, Tim Soverns, Joseph T. Hanlon
-
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis Drugs Aging (IF 2.8) Pub Date : 2023-09-08 Nadine Bittner, Cleo S. M. Funk, Alexander Schmidt, Felix Bermpohl, Eva J. Brandl, Engi E. A. Algharably, Reinhold Kreutz, Thomas G. Riemer
-
Methodological Considerations for Describing Medication Changes in Relation to Clinical Events and Death: An Applied Example in Patients with Type 2 Diabetes and Cancer Drugs Aging (IF 2.8) Pub Date : 2023-09-01 Karl Sebastian Johansson, Tonny Studsgaard Petersen, Mikkel Bring Christensen, Anton Pottegård
-
The Impact of Polypharmacy on Management of Lower Urinary Tract Symptoms in Parkinson’s Disease Drugs Aging (IF 2.8) Pub Date : 2023-08-31 Udit Saraf, Amit Batla, Ryuji Sakakibara, Jalesh N. Panicker
Lower urinary tract (LUT) symptoms are a common presentation of autonomic dysfunction in Parkinson’s disease (PD). Symptoms significantly impact quality of life and are associated with worsening of motor symptoms and increased risk for falls. Different medical co-morbidities can often contribute to LUT symptoms, and a thorough evaluation therefore becomes essential. The effects of medications used
-
Anticholinergic Burden and Cognitive Impairment in Nursing Homes: A Comparison of Four Anticholinergic Scales Drugs Aging (IF 2.8) Pub Date : 2023-08-24 Alessio Novella, Chiara Elli, Aladar Ianes, Luca Pasina
-
Discontinuation of Loop Diuretics in Older Patients with Chronic Stable Heart Failure: A Narrative Review Drugs Aging (IF 2.8) Pub Date : 2023-08-25 Chukwuma Okoye, Tessa Mazzarone, Cristina Cargiolli, Daniela Guarino
-
Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study Drugs Aging (IF 2.8) Pub Date : 2023-08-23 Xiyuan Zhou, Ge Yang, Xuejun Chen, Lixia Zhang
-
Theoretical Underpinnings of a Model to Reduce Polypharmacy and Its Negative Health Effects: Introducing the Team Approach to Polypharmacy Evaluation and Reduction (TAPER) Drugs Aging (IF 2.8) Pub Date : 2023-08-21 Dee Mangin, Larkin Lamarche, Jeffrey A. Templeton, Jennifer Salerno, Henry Siu, Johanna Trimble, Abbas Ali, Jobin Varughese, Amy Page, Christopher Etherton-Beer
-
A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult Drugs Aging (IF 2.8) Pub Date : 2023-08-18 Amie Taggart Blaszczyk, Monica Mathys, Jennifer Le
One-third of older adults with depression meet criteria for treatment resistance, typically defined as a lack of response to two or more adequate trials of an antidepressant. Treatment resistance contributes to an unfavorable prognosis, compromised medical outcomes, heightened disability, accelerated cognitive decline, and an elevated risk of developing dementia. Despite this significant morbidity
-
Hypertension Treatment in Frail Older Adults: A Systematic Review and Appraisal of Guidelines Drugs Aging (IF 2.8) Pub Date : 2023-08-18 Kaiyan Hu, Gang Zhou, Mengyao Jiang, Xiaohong Wei, Jing Yu, Li liu, Zhe Wang, Liyuan Feng, Mei Wu, Tao Li, Bin Ma
-
Evaluation and Treatment of Acute Trauma Pain in Older Adults Drugs Aging (IF 2.8) Pub Date : 2023-08-11 Minnie Merrick, Robert Grange, Sarah Rudd, David Shipway
-
Treating LUTS in Men with Benign Prostatic Obstruction: A Review Article Drugs Aging (IF 2.8) Pub Date : 2023-08-09 Liam Murad, David Bouhadana, David-Dan Nguyen, Bilal Chughtai, Kevin C. Zorn, Naeem Bhojani, Dean S. Elterman
Benign prostatic obstruction (BPO) is a prevalent condition that affects men, primarily toward their old age. The condition is often accompanied by lower urinary tract symptoms (LUTS), which can significantly impair a patient’s quality of life and lead to other medical complications. Accurate diagnosis of BPO is essential for effective management of complications secondary to BPO, and treatment plans
-
Trajectories of Benzodiazepine Use among Older Adults from a Concordance-with-Guidelines Perspective: A Nationwide Cohort Study Drugs Aging (IF 2.8) Pub Date : 2023-08-08 Sandy Maumus-Robert, Ana Jarne-Munoz, Marie Tournier, Bernard Bégaud, Antoine Pariente
-
Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review Drugs Aging (IF 2.8) Pub Date : 2023-07-24 Miles D. Witham, Antoneta Granic, Ewan Pearson, Sian M. Robinson, Avan A. Sayer
-
The Prognostic Utility of Anticholinergic Burden Scales: An Integrative Review and Gap Analysis Drugs Aging (IF 2.8) Pub Date : 2023-07-18 Henry Ukachukwu Michael, Okechukwu Enechukwu, Marie-Josée Brouillette, Robyn Tamblyn, Lesley K. Fellows, Nancy E. Mayo
-
Guideline-Directed Medical Therapies for Heart Failure with a Reduced Ejection Fraction in Older Adults: A Narrative Review on Efficacy, Safety and Timeliness Drugs Aging (IF 2.8) Pub Date : 2023-07-14 Lorenz Van der Linden, Julie Hias, Karolien Walgraeve, Mirko Petrovic, Jos Tournoy, Christophe Vandenbriele, Lucas Van Aelst
-
Management of Type 2 Diabetes in Frail Older Adults Drugs Aging (IF 2.8) Pub Date : 2023-07-11 Gulistan Bahat, Serdar Ozkok, Mirko Petrovic
-
Associated Factors to Efficacy and Tolerance of Immunotherapy in Older Patients with Cancer Aged 70 Years and Over: Impact of Coprescriptions Drugs Aging (IF 2.8) Pub Date : 2023-07-10 Marie Perret, Aurélie Bertaut, Julie Niogret, Sophie Marilier, Pierre Jouanny, Patrick Manckoundia, Leïla Bengrine-Lefevre, Valérie Quipourt, Jérémy Barben
Background Immunotherapy with immune checkpoint blockers (ICB) significantly improves the prognosis for an increasing number of cancers. However, data on geriatric populations taking ICB are rare. Objective This study aimed to identify factors associated with the efficacy and tolerance of ICB in an older population. Patients and Methods This retrospective monocentric study included consecutive patients
-
Age is No Barrier: CAR-T Therapy in Older Adults Drugs Aging (IF 2.8) Pub Date : 2023-07-11 Joseph E. Maakaron, Basem M. William
In the last decade, chimeric antigen receptor-T (CAR-T) cells have revolutionized the treatment of hematological malignancies. With six different products for five diseases in various settings, CAR-T use has increased, and the comfort level of prescribers continues to expand. These therapies carry substantial toxicities that may limit their applicability to all patient populations. In the registrational
-
Utility of Big Data to Explore Medication Adherence in Māori and Non-Māori Community-Dwelling Older Adults with Heart Failure in Aotearoa New Zealand: A Cross-sectional Study Drugs Aging (IF 2.8) Pub Date : 2023-06-29 Joanna Hikaka, Rebecca Abey-Nesbit, Brendon McIntosh, Philip J. Schluter, Prasad S. Nishtala, Richard Scrase, Hamish A. Jamieson
-
Association of Potentially Inappropriate Medication Classes with Mortality Risk Among Older Adults Initiating Hemodialysis Drugs Aging (IF 2.8) Pub Date : 2023-06-28 Rasheeda K. Hall, Abimereki D. Muzaale, Sunjae Bae, Stella M. Steal, Lori M. Rosman, Dorry L. Segev, Mara McAdams-DeMarco
-
Fall-Risk-Increasing Drugs and Gait Performance in Community-Dwelling Older Adults: Exploratory Results from the Gait and Brain Study Drugs Aging (IF 2.8) Pub Date : 2023-06-22 Abdelhady Osman, Mark Speechley, Shehzad Ali, Manuel Montero-Odasso
Background/Objective While several psychotropic and cardiovascular drugs have been identified as fall-risk-increasing drugs (FRIDs) in older adults, the intervening mechanisms linking FRIDs and falls are unclear. It is plausible that gait performance is an intermediate variable on the causal pathway between FRIDs and falls. The current evidence on the relationship between medication use and gait performance